To see all protocols that comply with the WHO Essential Medicine List 
 The following have occurred in patients receiving blinatumomab:
  • Cytokine Release Syndrome, which may be life-threatening or fatal
  • Neurological toxicities, which may be severe, life-threatening, or fatal
  • Reactivation of JC viral infection

Interrupt or discontinue blinatumomab as recommended if any of these adverse events occur.

Patients with leukaemia should be considered for inclusion into clinical trials. Link to ALLG website and ANZCTR website.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

28 Sep 2020